Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Mayo Clinic Laboratories, |
RCV002261650 | SCV002541740 | uncertain significance | not provided | 2021-06-18 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV003095885 | SCV002932816 | uncertain significance | Metachromatic leukodystrophy | 2022-04-16 | criteria provided, single submitter | clinical testing | This sequence change replaces glycine, which is neutral and non-polar, with aspartic acid, which is acidic and polar, at codon 117 of the ARSA protein (p.Gly117Asp). This variant is present in population databases (no rsID available, gnomAD 0.007%). This variant has not been reported in the literature in individuals affected with ARSA-related conditions. Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt ARSA protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Gelb Laboratory, |
RCV003095885 | SCV005046652 | not provided | Metachromatic leukodystrophy | no assertion provided | in vitro |